Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Breast Growth in Boys Taking J&J's Risperdal Was Known Since at Least 2004
- The risk that boys taking the atypical antipsychotic Risperdal might grow breasts was known as far back as 2004. The Wall Street Journal reports that the FDA heard about this worrying side effect in a meeting on Risperdal last week: The FDA’s Tom Laughren, who runs the psychiatric medicines...
- Blog posts 2008-11-26
- J&J and Risperdal: New Claims of Kickbacks and Fraudulent Marketing
- The news on Risperdal continues to get worse for Johnson & Johnson and its antipsychotic unit, Janssen Pharmaceuticals. Texas officials filed suit against the company alleging Medicaid fraud, kickbacks and improper marketing of the drug to children and the poor in that state. J&J denies the claims. ...
- Blog posts 2008-12-17
- Biederman's Finances: He Names His Own Price, and It's $550 an Hour
- Dr. Joseph Biederman, the Harvard Medical School and Massachusetts General Hospital Researcher, has been subpoenaed by federal prosecutors for all information he produced in litigation surrounding the alleged off-label promotion of Johnson & Johnson's Risperdal for children, according to the NYT. This means that the feds will...
- Blog posts 2009-03-29
- Why J&J "Deselected" 900 Reps Despite Sales Growth
- Johnson & Johnson's Ortho McNeil/Janssen unit is in the process of laying off about 900 staffers, according to Dow Jones Newswires. Sales and profits at J&J are both up overall. Sales went up from $61 billion to $63.4 billion last year, profit was up from $10.5 billion...
- Blog posts 2009-04-10
Additional Resources
- J&J Fined $5,000 Per Sales Rep Visit for Risperdal Mismarketing
- How bad could that Texas lawsuit against Johnson & Johnson for mismarketing Risperdal be? Try $5,000 per visit of a sales rep to a doctor. That was the formula used in a West Virginia state court case in which the state attorney general sued J&J and its...
- Blog posts 2009-03-03
- Risperdal Payments Result in Conviction for State Meds Official
- A Pennsylvania official who took $12,000 in fees and honoraria from Pfizer and Janssen while he was in charge of putting antipsychotics such as Risperdal on the state's dispensary lists for mental hospitals has been convicted of a "felony conflict of interest." Steve Fiorello pictured, the state's former director of...
- News items 2009-08-07
- FDA Approves New Injection Site for RISPERDAL® CONSTA® for Schizophrenia Treatment
- CAMBRIDGE, Mass. -- Alkermes, Inc. (NASDAQ: ALKS) today announced that patients with schizophrenia now have a new administration option for RISPERDAL([R]) CONSTA([R]) [risperidone Long-Acting Injection]. The U.S. Food and Drug Administration FDA has approved a new injection site, the deltoid muscle in the arm, for RISPERDAL CONSTA for the treatment...
- Research articles 2008-10-09
- Johnson & Johnson. (Active Pharmaceutical Ingredient Watch).(receives nonapprovable letter for Risperdal Consta)(Brief Article)
- JOHNSON & JOHNSON received a nonapprovable letter from the FDA for its schizophrenia drug Risperdal Consta ... JOHNSON & JOHNSON received a nonapprovable letter from the FDA for its schizophrenia drug Risperdal Consta risperidone, a long-acting injectable formulation of Risperdal that uses Alkermes Inc.'s...
- Research articles 2002-07-15
- Alkermes Announces RISPERDAL® CONSTA® Approved in Italy
- CAMBRIDGE, Mass. -- Alkermes, Inc. (Nasdaq: ALKS) today announced that its partner, Janssen-Cilag S.p.A., received approval from the Italian Regulatory Authorities to market RISPERDALR CONSTAR (risperidone long-acting injection), an atypical antipsychotic medication for the treatment of schizophrenia. Alkermes expects its partner to launch the product in Italy before the end...
- Research articles 2005-09-15
- The Money Trail in the J&J Risperdal/Biederman Case
- Like a car crash in slow motion, the years that drug companies have spent encouraging the idea that disruptive children ought to be medicated are resulting in ever more lurid revelations in the business press. Yesterday evening came news that a suit against Johnson & Johnson regarding its drug Risperdal...
- Blog posts 2008-11-25
- Janssen - Risperdal: "probably" busted!
- A sales representative for Johnson & Johnson's Janssen Pharmaceutica unit testified that he encouraged doctors to prescribe the antipsychotic drug Risperdal for unapproved uses. Matthew D. Thompson, testifying today in a trial over claims by a former co-worker, said that in 2002 he pushed doctors to consider prescribing Risperdal...
- News items 2009-10-29
- J&J Files NDA for New Formulation for Risperdal.(Johnson and Johnson's Janssen Pharmaceutical Products L.P.)(Brief Article)
- HOLDING ITS LEAD in the schizophrenia market, Johnson & Johnson's Janssen Pharmaceutical Products LP has filed a new drug application with the Food & Drug Administration for a long-acting injectable formulation of Risperdal risperidone. HOLDING ITS LEAD in the schizophrenia market, Johnson...
- Research articles 2001-09-10
- Alkermes Inc. (Active Pharmaceutical Ingredient Watch).(Risperdal Consta )(Brief Article)
- ALKERMES Inc. and partner Johnson & Johnson Pharmaceutical Research and Development LLC have received approval to market Risperdal Consta risperidone in Germany and the UK, the first approved long-acting injection of an atypical antipsychotic ALKERMES Inc. and partner Johnson & Johnson Pharmaceutical Research...
- Research articles 2002-08-19
- Alkermes to Expand Production Capacity for Risperdal Consta
- CAMBRIDGE, Mass. -- Alkermes, Inc. (Nasdaq: ALKS) today announced that the Company will expand production capacity for RisperdalR ConstaR (risperidone long-acting injection), an atypical antipsychotic medication approved for the treatment of schizophrenia. This expansion at Alkermes' Wilmington, Ohio, facility is designed to meet anticipated future demand for Risperdal Consta. Alkermes'...
- Research articles 2005-01-11
- Alkermes Announces Submission of New Drug Application for RISPERDAL® CONSTA® in Japan
- CAMBRIDGE, Mass. -- Alkermes, Inc. (Nasdaq: ALKS) today announced that the Japanese organization of its partner Janssen-Cilag, Janssen Pharmaceutica K.K., submitted a new drug application to the Pharmaceuticals and Medical Devices Agency PMDA for marketing approval in Japan of RISPERDAL([R]) CONSTA([R]) [risperidone long-acting injection], an atypical antipsychotic medication for the...
- Research articles 2006-12-20
- FDA: J&J's Risperdal and Lilly's Zyprexa Are Over-Used in Kids
- Johnson & Johnson and Eli Lilly can expect their atypical anti-psychotics to take a sales hit in light of some FDA officials' desire to see their use curbed in children. An FDA panel yesterday rejected the FDA's proposed routine monitoring of the safety of anti-psychotics in children and instead discussed...
- Blog posts 2008-11-19
- Risperdal Payments Result in Conviction for State Meds Official
- A Pennsylvania official who took $12,000 in fees and honoraria from Pfizer and Janssen while he was in charge of putting antipsychotics such as Risperdal on the state's dispensary lists for mental hospitals has been convicted of a "felony conflict of interest." Steve Fiorello, the state's former director of pharmacy...
- Blog posts 2008-12-24
- ALKERMES Inc.(contract with Janssen Pharmaceutica on Risperdal production)(Brief Article)
- ALKERMES Inc. has signed an agreement with Janssen Pharmaceutica to expand Alkermes' manufacturing capacity for the longacting ... ALKERMES Inc. has signed an agreement with Janssen Pharmaceutica to expand Alkermes' manufacturing capacity for the longacting injectable formulation of antipsychotic Risperdal risperdone, which ...
- Research articles 2001-11-05
- Supplemental New Drug Application for RISPERDAL® CONSTA® Submitted to the FDA for the Treatment of Frequently Relapsing Bipolar Disorder
- CAMBRIDGE, Mass. -- Alkermes, Inc. (NASDAQ: ALKS) today announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a Supplemental New Drug Application sNDA for RISPERDAL([R]) CONSTA([R]) [risperidone Long-Acting Injection] to the U.S. Food and Drug Administration FDA seeking approval for adjunctive maintenance treatment to delay...
- Research articles 2008-04-14
- Harvard's Biederman: "Save Me From NYT's Gardiner Harris!"
- Dr. Joseph Biederman, the controversial Harvard child psychiatrist who promoted the use of Johnson & Johnson's Risperdal antipsychotic in children, is begging a New Jersey judge to save him from New York Times reporter Gardiner Harris. Harris also sucks as a reporter, Biederman alleges in a letter...
- Blog posts 2009-03-20
- << Previous
- page 1 of 1
- Next >>
